View printer-friendly version

Download PDF

Emergent BioSolutions to Present at the Cowen & Company 27th Annual Health Care Conference

ROCKVILLE, Md.–(BUSINESS WIRE)–March 5, 2007–Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will present at the Cowen and Company 27th Annual Health Care Conference in Boston. Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions and Dr. Stephen N. Chatfield, chief scientific officer of Emergent BioSolutions, will provide a company overview and outline future growth opportunities at 3:10 pm EDT, Monday, March 12, 2007 at The Boston Marriott Copley Place, Boston, Massachusetts.

A webcast of the presentation will be available both live and by replay. To access both the live and archived webcast, please go to www.emergentbiosolutions.com, click on the “Investors” link and proceed to the “Webcasts & Presentations” section. The archived replay will be available 24 hours after the live presentation and will be accessible for 30 days.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. Immunobiotics are vaccines and immune globulins that induce or assist the body’s immune system to prevent or treat disease. The company’s biodefense business is focused on developing and commercializing immunobiotics for use against biological agents that are potential weapons of bioterrorism. The company’s commercial business is focused on developing immunobiotics for use against infectious diseases with significant unmet or underserved medical needs. More information on the company is available at www.emergentbiosolutions.com.